UK markets close in 7 hours 15 minutes

  • FTSE 100

    6,693.54
    -21.88 (-0.33%)
     

  • FTSE 250

    20,699.82
    -93.90 (-0.45%)
     

  • AIM

    1,194.21
    -3.88 (-0.32%)
     

  • GBP/EUR

    1.1235
    -0.0046 (-0.41%)
     

  • GBP/USD

    1.3679
    -0.0051 (-0.37%)
     

  • BTC-GBP

    22,953.86
    +749.32 (+3.37%)
     

  • CMC Crypto 200

    619.33
    +9.34 (+1.53%)
     

  • S&P 500

    3,853.07
    +1.22 (+0.03%)
     

  • DOW

    31,176.01
    -12.37 (-0.04%)
     

  • CRUDE OIL

    52.37
    -0.76 (-1.43%)
     

  • GOLD FUTURES

    1,863.20
    -2.70 (-0.14%)
     

  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     

  • HANG SENG

    29,447.85
    -479.91 (-1.60%)
     

  • DAX

    13,833.58
    -73.09 (-0.53%)
     

  • CAC 40

    5,557.34
    -33.45 (-0.60%)
     
Pharma:

US drug authority approves world's first long-acting HIV regimen

Cabenuva's injectable HIV treatment regimen — which is administered once a month — does not require daily pills

PM denies his decision to delay first lockdown led to more deaths

Boris Johnson has denied his decision to delay a lockdown at the start of the coronavirus pandemic led to more deaths.

Latest stories

  • Iran says oil product exports hit record high despite U.S. sanctions

    Iran has achieved record high exports of petroleum products despite U.S. sanctions, Oil Minister Bijan Zanganeh said in televised remarks on Friday. Zanganeh said former U.S. President Donald Trump and his secretary of state, Mike Pompeo, had "joined the dustbin of history, but we are alive and working with more hope to build the country". "The enemy and Trump wanted us to perish and die, our exports to reach zero," he said.

  • Ashley Banjo Defends Rufus Hound Over Comedian's Government Jibe On Dancing On Ice

    "Of course he is allowed to say it. That is his prerogative," the DOI judge has said.

  • Joe Biden's Oval Office: what changes has the new president made?

    Joe Biden's Oval Office: what changes has the new president made?From a Cesar Chavez bust and the removal of portraits, to a desk now piled high with orders tearing up Trump’s legacy

  • HBO Outlines its European Vision at Goteborg’s TV Drama Vision

    Göteborg’s TV Drama Vision, the drama series and TV industry strand of Scandinavia’s biggest film-TV festival, has unveiled further details of its works-in-progress and project showcases, as well as keynote speakers from HBO Europe to Walter Presents. As HBO Max lands in Europe during the second half of 2021, Antony Root, executive VP original programming […]

  • Gigi Hadid finally reveals the name of her baby girl with Zayn Malik

    The couple welcomed their daughter in September 2020.

  • Liverpool currently ‘not up to challenge’ of being a ‘special’ team, claims Graeme Souness

    The Reds are five without a win in the Premier League and have failed to score in their last four games, with Souness concerned some of the players are “shot”

  • Wheat Starch Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type ; Grade and End User Industry

    The wheat starch market was valued at US$ 1,016. 95 million in 2019 and is projected to reach US$ 1,203. 32million by 2027; it is expected to grow at a CAGR of 2. 3% during 2020–2027. Wheat starch has superior gelling, stabilizing, and thickening properties.New York, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Wheat Starch Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type ; Grade and End User Industry" - https://www.reportlinker.com/p06010117/?utm_source=GNW When used in food, wheat starch helps impart the desired texture and viscosity, along with enabling gel formulation, binding, and moisture retention.It is mainly employed as a thickening agent in the food industry.Wheat starch thickens the food through retrogradation and gelatinization.The heat causes the starch to absorb water and swell while increasing the clarity and viscosity.However, once it reaches the maximum viscosity level, the molecules move apart, leading to reduced viscosity.Further, when the product begins to cool again the viscosity increases, thus making the solution cloudy which leads to the formation of the gel. This is one of the reasons why the food and beverage manufactures prefer using wheat starch in food products. The use of heat starch is also increasing in baking these days. The modified wheat starch confers superior emulsifying properties in certain food products. It also finds application in confectioneries such as Turkish delight. It is also effective in improving the head retention in beer. It is also used in the making of sausages and meat rolls. Wheat starch is a major component of pasta and represents about 70% of its weight. Compared to other starch types, wheat starch increases the volume and tenderness of cakes and also helps in fat absorption in doughnuts. Wheat starch is commonly used in sweeteners such as glucose syrup, maltodextrin, and dextrose. It is employed as a stabilizer in sauces and puddings.On the basis of type, the wheat starch market is segmented into native wheat starch and modified wheat starch.In 2019, the native wheat starch segment dominated the market.The physical extraction of wheat starch separates gluten and other proteins.Native wheat starch is also a plant-based component used in foods derived from wheat.It is a white to off-white powder with a neutral smell and taste. It has an energy value of 4 kcal/g, i.e., similar to all other carbohydrates. Native wheat starch is used as a thickening, stabilizing, clouding, and glazing agent; moreover, it can also be used for binding and moisture retention. It is used in sugar confectioneries, bakery products, snacks, dairy products (such as cheese), alcoholic beverages, sauces and soups, pasta, ready meals, and meat and seafood (such as surimi).The wheat starch market is segmented into North America, Europe, Asia Pacific (APAC), South America, and Middle East and Africa (MEA).Asia Pacific held the significant share of the market in 2019, followed by Europe and North America.North America consists of developed economies such as the US and Canada, as well as developing nations such as Mexico.Surge in health-consciousness and changes in lifestyle propel the demand for wheat starch in the region.Thus, the major factors driving the growth of the wheat starch market in North America is the increasing inclination of the consumers toward convenience foods, including baked foods and RTC & RTE food items.The application of wheat starch as a replacement to fat owing to its gluten intolerant property supports the growth of wheat starch in the region.The European continent comprises economies such as Germany, France, Italy, the UK, and Russia. Transforming lifestyle trends concerning the food and beverages, and consumer goods industries has had a noteworthy influence on the wheat starch market in Europe. Moreover, the presence of well-established players such as Roquette Frères, Cargill Incorporated, and Archer Daniels Midland Company also contributes to the market in this region.The COVID-19 outbreak was first reported in Wuhan (China) in December 2019, and since then, it has spread at a fast pace across the globe.As of December 2020, the US, India, Brazil, Russia, France, the UK, Turkey, Italy, Spain, Germany, Argentina, Colombia and Mexico are among the worst-affected countries by this pandemic.According to the WHO, as of December there are ~ 80,773,033 COVID-19 affirmed cases and 1,783,619 death cases worldwide.The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.Food and beverages is one the world’s major industries suffering serious disruptions such as supply chain breaks, technology events cancellations, and office shutdowns.China is the global manufacturing hub and largest raw material supplier for various industries.The lockdown of various plants and factories in China is affecting the global supply chains and negatively impacting the manufacturing, delivery schedules, and material sales. Various companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia, and North America are affecting the business collaborations and partnerships opportunities.Cargill Incorporated, Roquette Freres, Manildra Group, MGP Ingredients, The Archer-Daniels-Midland Company, Agrana Group, Tereos SA, Crespel and Deiters, New Zealand Starch Company, and Sacchetto S.p.A are among the major players present in the global wheat starch market.Overall size of the global wheat starch market size has been derived in accordance with both primary and secondary sources.To begin the research process begins exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants typically involved in the process include industry experts, such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specialized in the wheat starch market.Read the full report: https://www.reportlinker.com/p06010117/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Epilepsy - Worldwide Market and Epidemiology Insights & Forecasts to 2030

    Dublin, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The "Epilepsy - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.The Epilepsy market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Epilepsy market size from 2017 to 2030.The report also covers current Epilepsy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.Geography Covered The United StatesEU5 (Germany, France, Italy, Spain, and the United Kingdom)Japan Study Period: 2017-2030DiagnosisSeveral tests are used to determine whether a person has a form of epilepsy and, if so, what kind of seizures the person has. These tests include: Imaging and MonitoringMedical HistoryBlood TestsDevelopmental, Neurological, and Behavioral Tests Epidemiology - Key FindingsThis section provides glimpse of the Epilepsy epidemiology in the 7MM. The total prevalent population of Epilepsy in the seven major markets was found to be 7,190,297 in 2017. However, the total diagnosed prevalent population in the 7MM was 5,216,490 in 2017.The diagnosed prevalent cases of Epilepsy, in the United States, were found to be 2,808,599 in 2017.In the United States, the number of cases of Generalized, Focal and Other determined and undetermined Epileptic seizures in Adults was 770,288, 1,482,440 and 169,560, respectively, in 2017.In the United States, the number of cases of Generalized, Focal and Other determined and undetermined Epileptic seizures in Children was 158,387, 212,471 and 15,452, respectively, in 2017.It was also found that in the United States, the number of males and females with Epilepsy was 1,477,323 and 1,331,276, respectively, in 2017.In the EU5 countries, the prevalence of Epilepsy was found to be maximum in Germany with 645,784 cases, followed by the United Kingdom with 641,720 cases in 2017. While, the least number of cases were found in Spain, with 403,591 cases in 2017.In Japan, the total prevalence of Epilepsy was estimated to be 1,012,659 in 2017. Country-wise EpidemiologyThe epidemiology segment also provides the Epilepsy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.Drug ChaptersThe drug chapter segment of the Epilepsy report encloses the detailed analysis of Epilepsy marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Epilepsy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.Marketed Drugs Valtoco: NeurelisEpidiolex: Greenwich BiosciencesFintepla (ZX 008): ZogenixBriviact: UCB BiopharmaXcopri (cenobamate): SK Life ScienceNayzilam (midazolam), nasal spray CIV: UCBDiacomit: Biocodex Emerging Drugs Ganaxolone: Marinus PharmaceuticalsAQST-203: Aquestive TherapeuticsCannabidiol: Insys TherapeuticsPadsevonil: UCBSoticlestat (TAK935/OV935): Takeda/Ovid TherapeuticsZygel (ZYN002): Zynerba Pharma Key Market FindingsThis section includes a glimpse of the Epilepsy 7MM market. The market size of Epilepsy in the seven major markets was estimated to be USD 1,847.46 Million in 2017.The United States accounts for the largest market size of Epilepsy, in comparison to EU5 (the United Kingdom, Germany, Italy, Spain, and France) and Japan.Among the EU5 countries, the United Kingdom had the highest market size with USD 118.23 Million in 2017, while France had the lowest market size of Epilepsy with USD 72.65 Million in 2017.The Japan Epilepsy market accounted for USD 121.90 Million in 2017. The United States Market OutlookThis section provides the total Epilepsy market size and market size by therapies in the United States.EU-5 Market OutlookThe total Epilepsy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.Japan Market OutlookThe total Epilepsy market size and market size by therapies in Japan are provided.Epilepsy Drugs UptakeThis section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Epilepsy market uptake by drugs; patient uptake by therapies; and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.Epilepsy Development ActivitiesThe report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.Pipeline Development ActivitiesThe report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Epilepsy emerging therapies.Competitive Intelligence AnalysisThe researchers perform competitive and market Intelligence analysis of the Epilepsy market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.Scope of the Report The report covers the descriptive overview of Epilepsy, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.Comprehensive insight has been provided into the Epilepsy epidemiology and treatment.Additionally, an all-inclusive account of both the current and emerging therapies for Epilepsy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.A detailed review of Epilepsy market; historical and forecasted is included in the report, covering the 7MM drug outreach.The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Epilepsy market. Report Highlights In the coming years, Epilepsy market is set to change due to the rising awareness of the disease, increased diagnosis and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.The companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.As per the analysis, Epilepsy can be of three kinds on the basis of seizure-type, namely, Generalized, Focal and other determined and undetermined seizures. These seizures come with a slight variation in children as well as adults.The publisher has also analysed gender-specific data regarding Epilepsy, which suggests that it is more prevalent in males than in females.Expected Launch of potential therapies, Libervant/Diazepam Buccal Soluble Film (Aquestive Therapeutics), UCB0942/Padsevonil (UCB Biopharma), Soticlestat (TAK-935/OV935) (Takeda), CX-8998 (Jazz Pharmaceuticals), Ganaxolone (Marinus Pharmaceuticals), PF-06372865/CVL-865 (Pfizer/Cerevel Therapeutics), Cannabidiol Oral Solution (Insys Therapeutics), Staccato Alprazolam (EngageTherapeutics/UCB), GWP42003-P (GW Research), Fintepla (Zogenix), Perampenal (Eisai) and Zygel (Zynerba), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Epilepsy.Currently, the first line treatment of Epilepsy involves the use AEDs either as monotherapies or combination therapy. Additionally, the second line and third line treatment option for epileptic patients also involves the use of AEDs itself. However, the third line treatment option also includes Surgery, VNS, Deep Brain stimulation, etc. Furthermore, certain Mono or Adjunctive therapies are also used for treating Epilepsy. Market Insights What was the Epilepsy market share (%) distribution in 2017 and how it would look like in 2030?What would be the Epilepsy total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?What are the key findings pertaining to the market across the 7MM and which country will have the largest Epilepsy market size during the forecast period (2020-2030)?At what CAGR, the Epilepsy market is expected to grow at the 7MM level during the forecast period (2020-2030)?What would be the Epilepsy market outlook across the 7MM during the forecast period (2020-2030)?What would be the Epilepsy market growth till 2030 and what will be the resultant market size in the year 2030?How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Companies Mentioned Aquestive TherapeuticsBiocodexEisai PharmaceuticalsGlaxoSmithKlineGreenwich BiosciencesJanssen PharmaceuticalsLundbeckMeda PharmaceuticalsNeurelisPfizerQuestcor Pharmaceuticals/Mallinckrodt PharmaceuticalsRocheSK Life ScienceSupernus PharmaceuticalsUCBZogenix For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7mrire Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS

    Auction date2021-01-22Loan3111Coupon0.125 %ISIN-codeSE0007045745Maturity2032-06-01Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,674Volume bought, SEK mln500Number of bids14Number of accepted bids6Average yield-1.592Lowest accepted yield-1.598Highest yield-1.585% accepted at lowest yield 33.33 Auction date2021-01-22Loan3112Coupon0.125 %ISIN-codeSE0008014062Maturity2026-06-01Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,450Volume bought, SEK mln500Number of bids10Number of accepted bids3Average yield-1.727Lowest accepted yield-1.731Highest yield-1.719% accepted at lowest yield 100.00

  • US drug authority approves world's first long-acting HIV regimen

    Cabenuva's injectable HIV treatment regimen — which is administered once a month — does not require daily pills.

  • Serving Met Police officer who was shielding dies after testing positive for COVID

    PC Michael Warren, a serving Met Police officer who was shielding at home and working remotely, died after testing positive for COVID.

  • Nissan investment in UK post-Brexit a ‘great vote of confidence’, says PM

    The Japanese car giant said the trade agreement will redefine the UK's automotive industry.

  • Evli focuses on growing its asset management business and commences a strategic evaluation regarding the future of banking services

    EVLI BANK PLC STOCK EXCHANGE RELEASE JANUARY 22, 2021, AT 11.05 AM (EET/EEST) On January 22, 2021, Evli Bank's Board of Directors decided to commence a strategic evaluation on the banking services future. The financial significance of banking services for Evli is limited, its share of Evli Group's net sales in 2020 was less than five percent. Evli's strategic goal is to strengthen its position as a leading Nordic wealth manager. The focus of the strategy is on developing and growing international sales and alternative asset classes, as well as strengthening domestic market leadership in both private and institutional wealth management and among corporate clients. Investments into customer experience and leadership in taking responsibility factors into account in investment activities are at the core of Evli’s strategy. In the evaluation, Evli assesses among other things the business and financial effects of a possible exit from the banking services. The evaluation has no effect on Evli's product and service offering or customer service. “The study is part of the implementation of Evli's strategy and a continuum of the long-term development of Evli's business. Evli has a growth strategy in which profitability is strongly linked to business development through the growth of assets under management. It is estimated that a possible exit from banking service would free up both financial and human resources for the development of existing and new products and services in order to strengthen Evli's market position”, says Maunu Lehtimäki, CEO of Evli Bank Plc. If Evli decided, as a result of the evaluation process, that it will exit from banking services, Evli would apply for an investment service authorization and continue its operations as an investment firm. It is currently estimated that the change would take place at the earliest during the third quarter of 2021.The waiver of the credit institution license would require, among other things, the approval of Evli's Annual General Meeting and the supervisory authority. Evli estimates that the evaluation process will be finalized during the first half of 2021. Evli currently offers banking services that support clients’ investment activities and wants to ensure their availability in the future as well. As part of the evaluation process, Evli is identifying a suitable partner through which Evli would be able to offer its clients at least as comprehensive banking services as Evli currently offers. EVLI BANK PLC Additional information: Maunu Lehtimäki, CEO, Evli Bank Plc, tel. (0)50 553 3000, maunu.lehtimaki@evli.com Evli Bank Plc Evli is a bank specialized in investments that helps institutions, corporations and private persons increase their wealth. The product and service offering includes mutual funds, asset management and capital markets services, alternative investment products, equity research, incentive plan design and administration as well as Corporate Finance services. The company also offers banking services that support clients' investment operations. Evli is the highest ranked and most used institutional asset manager in Finland*. Evli has a total of EUR 14.1 billion in client assets under management (net 12/2020). Evli Group's equity capital totals EUR 95.4 million and its BIS capital adequacy ratio is 15.2 percent (December 31, 2020). The company has around 250 employees. Evli Bank Plc's B shares are listed on Nasdaq Helsinki Ltd. *KANTAR SIFO Prospera External Asset Management Finland 2015, 2016, 2017, 2018, 2019 and SFR Scandinavian Financial Research Institutional Investment Services, Finland 2015, 2016, 2017, 2018. Distribution: Nasdaq Helsinki Ltd, main media, www.evli.com

  • FIFA ex-president Blatter was in coma after heart surgery, daughter says

    Former FIFA president Sepp Blatter spent a week in an artificially induced coma after heart surgery last month, his daughter has told Swiss media. "Just before Christmas, he had to go to the hospital for heart surgery," Corinne Blatter said in an interview with CH Media, adding the operation had been expected to be routine. Blatter, who was FIFA president for 17 years, was suspended and later banned by the soccer body's ethics committee after becoming the subject of criminal proceedings in Switzerland in 2015.

  • Alison Brie reveals the hilarious audition process for Hannah Montana!

    She revealed how she managed to bag a part in 2006

  • Boris Johnson To Hold Downing Street Press Conference On Covid

    Prime minister will hold briefing at 5pm amid speculation new rules could be introduced.

  • Hannity Gets Blunt Lesson About Time Following 'Biden's Disastrous First Week' Claim

    The Fox News host slammed Biden’s first week in office before Donald Trump's successor had even completed his first full day.

  • Whole Slide Imaging Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type ; Application ; End User

    The whole slide imaging market was valued at US$ 419. 52 million in 2019 and is projected to reach US$ 1,582. 12 million by 2027; it is expected to grow at a CAGR of 18. 1% during 2020–2027. Technological advancements in whole slide imaging and increase in adoption of digital pathology.New York, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Whole Slide Imaging Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type ; Application ; End User" - https://www.reportlinker.com/p06010118/?utm_source=GNW However, the high cost involved in the installation and maintenance of whole slide imaging is expected to hinder the market growth.Whole slide imaging technology deals with the acquisition of high-speed, high-resolution slide images for pathology workflow.The technology is also known as virtual pathology and plays major role in the digital pathology.Whole slide imaging is responsible for image archiving and sharing. In addition, these images can also utilized for diagnosis by pathologists by generating digital workflow.The global whole slide imaging market is segmented on the basis of type, application and end user.Based on type, the whole slide imaging market is segmented into hardware, software, and services.The hardware segment is further sub-segmented as scanners, microscopes, and cameras.The hardware segment held the largest share of the market in 2019.Also, the same segment is estimated to register the highest CAGR in the market during the forecast period.Based on application, the whole slide imaging market is segmented into telepathology, cytopathology, immunohistochemistry, and hematopathology.The telepathology segment held the largest share of the market in 2019 however, immunohistochemistry segment is estimated to register the highest CAGR in the market during the forecast period. On the basis of end user, the whole slide imaging market has been segmented into hospitals, pharmaceutical and biopharmaceutical companies, laboratories, and academic research institutions. The academic research institutes held the largest share of the market in 2019, however, pharmaceutical and biopharmaceutical companies segment is estimated to register the highest CAGR in the market during the forecast period.European Federation of Pharmaceuticals Industries Associations, Canada Foundation of Innovation, and National Institute of Health are a few of the primary and secondary sources referred to while preparing the report on the whole slide imaging market.Read the full report: https://www.reportlinker.com/p06010118/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Global Gastroparesis Market and Epidemiology Insights 2017-2030 - Total Prevalence, Type-specific, Gender-specific, Severity-specific, Total Diagnosed

    Dublin, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The "Gastroparesis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. Gastroparesis - Epidemiology Forecast to 2030 delivers an in-depth understanding of the disease, historical and forecasted Gastroparesis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Study Period: 2017-2030Epidemiology PerspectiveThe disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Gastroparesis, Gender-specific Prevalence of Gastroparesis, Severity-specific Prevalence of Gastroparesis, Type-specific Prevalence of Gastroparesis and Total Diagnosed Prevalent Population of Gastroparesis a scenario of Gastroparesis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.Detailed Epidemiology Segmentation The total prevalent population of gastroparesis in the 7MM is expected to rise from 33,690,400 in 2017.As per estimates, the highest prevalence of gastroparesis was observed in the United States with 13,019,321 cases in 2017, which is likely to rise by 2030.As per the analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.According to the analysis, it has been observed that mild cases are more prominent in comparison to moderate-to-severe. In the United States, 7,811,592 mild cases were observed in 2017, i.e., 60% of the gastroparesis patient pool. Additionally, moderate-to-severe accounted for 40% of the gastroparesis patient pool.Among the major types of gastroparesis, i.e., idiopathic, diabetic and post-surgical gastroparesis, idiopathic gastroparesis accounts for a higher number of gastroparesis cases.Among the EU5 countries, in 2017, Germany had the highest prevalent population of gastroparesis followed by Spain and Italy. On the other hand, the United Kingdom had the lowest prevalent population of Gastroparesis. Scope of the Report The report covers the descriptive overview of Gastroparesis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.The report assesses the disease risk and burden and highlights the unmet needs of Gastroparesis.The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Gastroparesis, Total Diagnosed and Treated Cases of Gastroparesis. Key Questions Answered What is the disease risk, burden and unmet needs of Gastroparesis?What is the historical Gastroparesis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?What would be the forecasted patient pool of Gastroparesis at the 7MM level?What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastroparesis?Out of the countries mentioned above, which country would have the highest prevalent population of Gastroparesis during the forecast period (2020-2030)?At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)? Key Topics Covered 1 Key Insights2 Gastroparesis: Market Overview at a Glance2.1. Total Market Share (%) Distribution of Gastroparesis in 20172.2. Total Market Share (%) Distribution of Gastroparesis in 20303 Executive Summary4 SWOT Analysis5 Gastroparesis: Disease Background and Overview5.1 Introduction5.2 Types of Gastroparesis: Based on Causes5.2.1 Idiopathic Gastroparesis (IG)5.2.2 Diabetic Gastroparesis (DGp)5.2.3 Iatrogenic and Postsurgical Gastroparesis5.3 Clinical Signs and Symptoms5.4 Mechanisms or pathophysiology of gastroparesis5.5 Diagnosis of Gastroparesis6 Recognized Establishments7 Epidemiology and Patient Population7.1 Key Findings7.2 Epidemiology Methodology7.3 Total Prevalence of Gastroparesis in the 7MM7.4 Type-specific Prevalence of Gastroparesis in the 7MM7.5 Gender-specific Prevalence of Gastroparesis in the 7MM7.6 Severity-specific Prevalence of Gastroparesis in the 7MM7.7 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM8 United States Epidemiology8.1 Assumptions and Rationale8.2 Total Prevalence of Gastroparesis in the United States8.3 Type-specific Prevalence of Gastroparesis in the United States8.4 Gender-specific Prevalence of Gastroparesis in the United States8.5 Severity-specific Prevalence of Gastroparesis in the United States8.6 Total Diagnosed Prevalence of Gastroparesis in the United States9 EU5 Epidemiology9.1 Germany Epidemiology9.2 France Epidemiology9.3 Italy Epidemiology9.4 Spain Epidemiology9.5 United Kingdom Epidemiology10 Japan10.1 Assumptions and Rationale10.2 Total Prevalence of Gastroparesis in Japan10.3 Type-specific Prevalence of Gastroparesis in Japan10.4 Gender-specific Prevalence of Gastroparesis in Japan10.5 Severity-specific Prevalence of Gastroparesis in Japan10.6 Total Diagnosed Prevalence of Gastroparesis in Japan For more information about this report visit https://www.researchandmarkets.com/r/atgajs Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Pound dips as UK lockdown could last into summer

    Weaker-than-expected retail data added to the gloom over the prospects for the UK economy.